The Silverstein Foundation for Parkinson’s with GBA is supporting early work by AcureX Therapeutics to bring into patient testing potential disease-modifying treatments for Parkinson’s disease. Specifically, grant funding will go to advance the development of small molecule compounds targeting the path involving a specific protein in mitochondria — the…
Bial has entered into an exclusive agreement to market upon approval in Europe APL-130277 — Sunovion Pharmaceuticals‘ sublingual (under the tongue) film of apomorphine for off episodes in Parkinson’s disease. Under the agreement’s terms, Bial will be responsible for preparing a marketing authorization application for regulatory agencies there — drawing on…
A $200,000 gift from the Cargill family will help to support studies into gait that is affected by Parkinson’s disease. The money, from the estate of Bob and Sara Lou Cargill and given by their daughter Sara Beth Lee and her husband John Lee, who has Parkinson’s, will go toward…
Transcranial stimulation — a noninvasive procedure that sends low-level electric currents to certain brain regions — may boost the benefits of aerobic exercise and improve gait for people with idiopathic Parkinson’s disease, a small study reports. “We found that transcranial stimulation activated the pre-frontal cortex, a brain region that Parkinson’s…
Shape Therapeutics and Roche have entered into a strategic collaboration and license agreement to develop RNA-based gene therapies for Parkinson’s, Alzheimer’s, and rare diseases. Under the terms of the agreement, Shape will use its proprietary RNA technologies to leverage molecular machinery already present in human cells to…
Patient dosing has been completed in the Phase 2a clinical trial testing ANVS401, Annovis Bio’s investigational therapy for Alzheimer’s disease and Parkinson’s disease. An additional 40 patients with Parkinson’s disease were treated with ANVS401, with the company now preparing to share final safety and efficacy data later this year. According to…
A new hydrogel matrix appears to ease the delivery of therapeutic stem cells into the brain, a necessary step in potentially using these cells to treat Parkinson’s disease. In animal models, this hydrogel was found to provide a safe scaffold for stem cells to differentiate into dopamine-producing nerve cells —…
Farnesol, a natural compound of some herbs and fruits in commercial use, was seen to protect nerve cells in the brain and possibly restore some of these cells to health in multiple mouse models of Parkinson’s disease. Specifically, the compound prevented the loss of dopamine-producing neurons — nerve cells…
Inhibikase Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to start a Phase 1 clinical trial evaluating its investigational, once-daily, oral medicine IkT-148009 in patients with Parkinson’s disease. The clearance comes after the agency reviewed the safety, tolerability and pharmacokinetic data from a Phase 1 study…
A committee of the European Medicines Agency (EMA) is recommending the refusal of marketing authorization for Nouryant (istradefylline) — approved as Nourianz in the U.S. — as a medication for treating off episodes in Parkinson’s disease in the EU. In its opinion, the Committee for Medicinal Products for Human…
Get regular updates to your inbox.